通用中文 | 门冬胰岛素 | 通用外文 | Insulin Aspart |
品牌中文 | 品牌外文 | Novorapid Flexpen | |
其他名称 | 胰岛素天冬氨酸 | ||
公司 | 诺和诺德(novo nordisk) | 产地 | 丹麦(Danmark) |
含量 | 100iU/ml(3 ml) | 包装 | 5支/盒 |
剂型给药 | prefilled syringe | 储存 | 2度-8度(冰箱冷藏,禁止冷冻) |
适用范围 | 胰岛素依赖的糖尿病患者 |
通用中文 | 门冬胰岛素 |
通用外文 | Insulin Aspart |
品牌中文 | |
品牌外文 | Novorapid Flexpen |
其他名称 | 胰岛素天冬氨酸 |
公司 | 诺和诺德(novo nordisk) |
产地 | 丹麦(Danmark) |
含量 | 100iU/ml(3 ml) |
包装 | 5支/盒 |
剂型给药 | prefilled syringe |
储存 | 2度-8度(冰箱冷藏,禁止冷冻) |
适用范围 | 胰岛素依赖的糖尿病患者 |
活性物质胰岛素天冬氨酸
ATX codeA10AB05胰岛素天冬氨酸
药理组物质降钙素
降血糖药是短效人胰岛素类似物[胰岛素]
香精分类(ICD-10)
E10胰岛素依赖型糖尿病
碳水化合物代谢的减少,糖尿病,糖尿病胰岛素糖,1型糖尿病,糖尿病酮症酸中毒,胰岛素依赖性糖尿病,胰岛素依赖性糖尿病,昏迷高渗性非酮症酸性糖尿病不规则形式,违反碳水化合物代谢,1型糖尿病,I型糖尿病,胰岛素依赖性糖尿病,1型糖尿病
E11非胰岛素依赖型糖尿病
糖尿病糖尿病,碳水化合物代谢的减少,糖尿病胰岛素不依赖糖,糖尿病糖2型,2型糖尿病,非胰岛素依赖性糖尿病,非胰岛素依赖性糖尿病,非胰岛素依赖性糖尿病,胰岛素抵抗,胰岛素抵抗糖尿病,糖尿病乳酸菌,违反碳水化合物代谢,2型糖尿病,II型糖尿病,成年糖尿病,老年糖尿病,糖尿病胰岛素不依赖,2型糖尿病,糖胰岛素依赖型糖尿病II型
组成
NovoRapid®Penfill®
皮下和静脉内给药溶液1 ml
活性物质:
胰岛素天冬氨酸100 ED(3.5 mg)
辅助物质:甘油 - 16 mg; 苯酚 - 1.5mg; 甲酚 - 1.72mg; 锌 - 19.6μg(以氯化锌的形式); 氯化钠 - 0.58毫克; 磷酸氢二钠二水合物 - 1.25mg; 氢氧化钠2M - 约2.2mg; 盐酸2M - 约1.7mg; 注射用水 - 高达1毫升
一个墨盒含有3ml相当于300U的溶液
NovoRapid®FlexPen®
皮下和静脉内给药溶液1 ml
活性物质:
胰岛素天冬氨酸100 ED(3.5 mg)
辅助物质:甘油 - 16 mg; 苯酚 - 1.5mg; 甲酚 - 1.72mg; 锌 - 19.6μg(以氯化锌的形式); 氯化钠 - 0.58毫克; 磷酸氢二钠二水合物 - 1.25mg; 氢氧化钠2M - 约2.2mg; 盐酸2M - 约1.7mg; 注射用水 - 高达1毫升
一个注射器笔包含3ml相当于300U的溶液
剂型说明
透明无色溶液。
药理作用
药理作用 - 低血糖。
药效学
胰岛素天冬氨酸是通过使用酿酒酵母菌株的重组DNA生物技术的方法产生的短效人胰岛素类似物,其中B28位置的氨基酸脯氨酸被天冬氨酸取代。
与细胞的外部细胞质膜的特异性受体相互作用并形成刺激细胞内过程的胰岛素 - 受体复合物,包括。 合成一些关键酶(包括己糖激酶,丙酮酸激酶,糖原合成酶)。 减少血糖是由于,包括 增加细胞内运输,增加消化,刺激脂肪生成,糖原生成,肝脏产生葡萄糖的速度降低。
在位置B28的氨基酸脯氨酸取代天门冬氨酸胰岛素门冬胰岛素降低分子形成六聚体的趋势,这在正常胰岛素溶液中观察到。 在这方面,天冬氨酰胰岛素从皮下脂肪中更快地被吸收,开始比可溶性人胰岛素起作用。 胰岛素天冬氨酸在摄入后的前4小时内强烈地降低血糖,而不是可溶性人胰岛素。 胰岛素后天冬氨酸的作用时间短于可溶性人胰岛素。
在给药后,药物的作用在给药后10-20分钟内开始。 在注射后1-3小时观察到最大效果。 药物的持续时间为3-5小时。
涉及1型糖尿病患者的临床研究表明,与可溶性人胰岛素相比,胰岛素门冬胰岛素的夜间低血糖风险降低。 昼夜低血糖风险不能可靠地增加。
胰岛素天冬氨酸是基于摩尔浓度指数的等位可溶性人胰岛素。
成人。 当胰岛素与可溶性人胰岛素相比时,与1型糖尿病患者相关的临床研究显示餐后血糖浓度较低。
老人 进行老年2型糖尿病患者胰岛素门冬胰岛素和可溶性人胰岛素的药代动力学和药效学(PK / PD)的随机双盲交叉研究(19例65-83岁,平均年龄70岁) 。 老年患者胰岛素门冬胰岛素和可溶性人胰岛素的药效学性质差异与健康志愿者和年龄较小的糖尿病患者相似。
儿童和青少年。 与可溶性人胰岛素相比,在儿童中使用天门冬胰岛素显示出与长期血糖控制相似的结果。
在儿童(26例2至6岁)中进行饭后使用可溶性人胰岛素和餐后胰岛素的临床研究; 并对儿童(6-12岁)和青少年(13-17岁)进行单剂量FK / PD研究。 儿童胰岛素门冬胰岛素的药效学特征与成年患者相似。
怀孕。 胰岛素门冬胰岛素和人胰岛素治疗1型糖尿病孕妇的相对安全性和疗效的临床研究(322例检查孕妇,157例接受天门冬胰岛素,165人胰岛素),怀孕期间胰岛素门冬胰岛素没有显示不良反应或胎儿健康/新生婴儿。
27名妊娠糖尿病患者接受了门冬胰岛素和人胰岛素(14名妇女接受了天门冬胰岛素,13人胰岛素)的临床研究表明,与胰岛素门冬胰岛素饮食后,安全性状况与葡萄糖控制有显着改善。
临床前安全数据
根据普遍接受的药物安全性研究,再利用毒性,遗传毒性和生殖毒性的数据,临床前研究尚未发现对人类有任何危害。
在体外试验中,包括与胰岛素和IGF-1受体的结合以及对细胞生长的影响,胰岛素门冬胰岛素的行为与人胰岛素的行为非常相似。 研究结果还表明,胰岛素门冬胰岛素与胰岛素受体的结合解离等同于人胰岛素的结合。
药代动力学
在施用胰岛素后,血浆中的天冬氨酸Tmax平均比施用可溶性人胰岛素的2倍小。 血浆中的Cmax平均值(492±256)pmol / l,并且在给予1型糖尿病患者0.15U / kg剂量的剂量后40分钟达到。 4-6小时后胰岛素的浓度恢复到基线。 2型糖尿病患者的吸收率略低,这导致较低的Cmax(352±240)pmol / L和较长的Tmax(60分钟)。 与可溶性人胰岛素相比,使用天门冬胰岛素时,Tmax的个体间变异性显着降低,而胰岛素的Cmax表示的变异性较高。
1型糖尿病儿童药物动力学(6-12岁)和青少年(13-17岁)。 具有Tmax的两个年龄组的胰岛素门冬胰岛素的吸收都很快,与成年人相似。 然而,两个年龄组的Cmax有差异,这强调了药物的个体剂量的重要性。
老人 老年患者(65-83岁,平均年龄70岁)2型糖尿病患者胰岛素门冬胰岛素与可溶性人胰岛素的药代动力学差异与健康志愿者和年龄较小的糖尿病患者相似。 在老年患者中,观察到吸收率降低,导致Tmax-82(可变性为60-120)min,而Cmax相同,而在年轻患者中观察到2型糖尿病,略少比1型糖尿病。
缺乏肝功能。 进行药代动力学研究,在24例患者中引入单剂量的门冬胰岛素,其肝功能范围从正常到严重的紊乱形式。 在肝功能受损的人群中,天门冬氨酸胰岛素的吸收速率降低并且更不稳定,导致肝功能正常的个体的Tmax从约50分钟升高至约85分钟,肝功能受损中度至严重者严重程度。 血浆中的AUC,Cmax和总清除率(Cl / F)在具有降低和正常肝功能的个体中是相似的。
缺乏肾功能。 对18例肾功能范围从正常到严重形式障碍的患者进行胰岛素门冬胰岛素的药代动力学研究。 没有发现Cl肌酐对AUC,Cmax,Tmax胰岛素门冬胰岛素的明显作用。 数据仅限于中,重型肾功能衰竭患者的指标。 研究中不包括需要透析的肾功能不全者。
迹象
成人,青少年和2岁以上儿童的糖尿病。
禁忌
增加对胰岛素门冬胰岛素或药物的任何成分的个体敏感性。
不要在2岁以下的儿童中使用NovoRapid®Penfill®/FlexPen®,尚未进行2岁以下儿童的临床研究。
适用于怀孕和哺乳期
NovoRapid®Penfill®/FlexPen®可在怀孕期间服用。 来自两个随机对照临床试验(157 + 14检查孕妇)的数据显示,与人胰岛素相比,妊娠期或胎儿/新生儿健康期间胰岛素门冬胰岛素没有不良反应(见药效学)。
建议在整个怀孕期间和怀孕期间仔细监测血糖水平并监测怀孕妇女患有糖尿病(1型,2型或妊娠期糖尿病)。 一般来说,胰岛素的需求在妊娠期减少,妊娠第二和第三个三个月逐渐上升。 出生不久后,胰岛素的需要迅速恢复到怀孕前的水平。
在母乳喂养期间,可以使用NovoRapid®Penfill®/FlexPen®,因为向母亲喂养胰岛素不会对孩子构成威胁。 然而,可能需要调整药物的剂量。
副作用
在使用药物NovoRapid®Penfill®/FlexPen®的患者中观察到的不良反应主要是由于胰岛素的药理作用。
最常见的不良反应是低血糖。
副作用的发生率因患者群体,剂量方案和血糖控制而异(见下文)。
在胰岛素治疗的初期阶段,可能发生屈光不良,注射部位的水肿和反应(疼痛,发红,荨麻疹,炎症,血肿,注射部位肿胀和瘙痒)。 这些症状通常是短暂的。 血糖控制的快速改善可导致急性疼痛神经病变的状态,这通常是可逆的。 胰岛素治疗的强化与碳水化合物代谢控制的显着改善可能导致糖尿病性视网膜病变的状态暂时恶化,而血糖控制的持续改善降低了糖尿病性视网膜病变进展的风险。
所选不良反应的描述
过敏反应。 已经注意到非常罕见的广泛性超敏反应(包括广泛性皮疹,瘙痒,出汗增加,胃肠道疾病,血管性水肿,呼吸困难,心悸,降血压)。
低血糖症。 低血糖是最常见的副作用。 如果胰岛素的剂量相对于胰岛素的需要太高,可能会发展。 严重的低血糖可导致意识丧失和/或抽搐,脑功能的暂时或不可逆的破坏直到致命的结果。 低血糖症状往往突然发展。 它们可能包括冷汗,皮肤苍白,疲劳,紧张或震颤,焦虑感,异常疲劳或虚弱,定向受损,集中度降低,嗜睡,严重饥饿,视力障碍,头痛,恶心和心悸。 临床研究表明,低血糖发生率根据患者群体,给药方案和血糖控制而变化。 临床研究显示接受胰岛素门冬胰岛素治疗的患者与使用人胰岛素制剂的患者之间低血糖发生发生总体发生率无差异。
脂肪代谢障碍。 有报道称罕见的脂肪营养不良病例。 脂肪营养不良可以在注射部位发展。
相互作用
有一些影响胰岛素需求的药物。 胰岛素的低血糖作用增加口服降糖药物,MAO抑制剂,ACE抑制剂,碳酸酐酶抑制剂,非选择性β-肾上腺素阻滞剂,溴隐亭,磺胺类药物,合成代谢类固醇,四环素,氯贝丁酯,酮康唑,甲苯达唑,吡哆醇,茶碱,环磷酰胺,芬氟拉明,锂制剂,水杨酸。
胰岛素的降血糖作用由口服避孕药,GCS,甲状腺激素,噻嗪类利尿剂,肝素,三环抗抑郁药,拟交感神经药,生长激素,达那唑,可乐定,BCC,二氮嗪,吗啡,苯妥英,尼古丁减弱。
β受体阻滞剂可以掩盖低血糖症状。
奥曲肽/兰瑞肽可以增加和减少对胰岛素的需求。
酒精可以增强和降低胰岛素的低血糖作用。
不兼容。 当添加到药物NovoRapid®Penfill®/FlexPen®中时,某些药物,例如含有硫醇或亚硫酸盐基团的药物可能会导致天门冬胰岛素的破坏。 药物NovoRapid®Penfill®/FlexPen®不应与其他药物混合。 异丙胰岛素和输注溶液,在“给药方法和剂量”一节中描述。
给药和管理
P / to,in / in。
NovoRapid®Penfill®/FlexPen®是一种快速作用的胰岛素类似物。 NovoRapid®Penfill®/FlexPen®的剂量由医生单独根据患者的需要决定。 通常该药物与中等持续时间或长期作用的胰岛素制剂组合使用,每天至少施用1次。 为了达到最佳的血糖控制,建议定期测量血液中葡萄糖的浓度并调整胰岛素的剂量。
通常,成人和儿童的每日胰岛素需求量为0.5至1U / kg。 当饭前服用制剂时,可通过NovoRapid®Penfill®/FlexPen®提供50-70%的胰岛素需求,胰岛素的剩余需要由长效胰岛素提供。 增加患者的身体活动,改变习惯性饮食或并发疾病可导致需要进行剂量调整。
NovoRapid®Penfill®/FlexPen®比可溶性人胰岛素具有更快的起始时间和更短的作用时间。 由于更快的作用开始,应通常在饭前进行NovoRapid®Penfill®/FlexPen®,必要时可在饭后不久进行。
由于与人类胰岛素相比,作用时间较短,接受NovoRapid®Penfill®/FlexPen®的患者发生夜间低血糖的风险较低。
特殊病人群体 与使用其他胰岛素制剂一样,老年患者和肾或肝功能不全的患者应更密切地监测血液中葡萄糖的浓度,并单独调整胰岛素的剂量。
儿童和青少年。 代替可溶性人胰岛素,当需要药物的快速起效时,优选使用NovoRapid®Penfill®/FlexPen®,例如当儿童难以观察注射和摄入。
从其他胰岛素制剂翻译。 将患者从其他胰岛素制剂转移至NovoRapid®Penfill®/FlexPen®时,可能需要对NovoRapid®Penfill®/FlexPen®和基础胰岛素进行剂量调整。
将NovoRapid®Penfill®/FlexPen®注射到腹壁,大腿,肩部,三角肌或臀部区域。 同一体内部位的注射部位应定期更换,以减少发生脂肪营养不良的风险。 与所有胰岛素制剂一样,sc,注射到前腹壁提供比在其他地方注射更快的吸收。 作用的持续时间取决于剂量,给药位置,血流强度,体温和身体活动水平。 然而,不管注射部位的位置如何,比可溶性人胰岛素的起效更快。
NovoRapid®可用于为胰岛素输注设计的胰岛素泵中延长的皮下胰岛素输注(CPII)。 PPII应在腹壁前方制成。 地点输液应定期更换。
当使用胰岛素泵进行输液时,NovoRapid®不应与其他类型的胰岛素混合。
使用FPII的患者应该在使用泵,适当的储存器和泵的管道系统方面进行充分的培训。 输液器(管和导管)应根据输液器附带的用户手册进行更换。
使用PPII接受NovoRapid®的患者应在输注系统破裂的情况下增加胰岛素。
四,介绍 如果需要,可以IV,但仅由合格的医务人员管理NovoRapid®。
对于IV介绍,使用NovoRapid®100U / ml制剂的输注系统,其浓度为0.05至1U / ml的胰岛素门冬胰岛素在0.9%氯化钠溶液,5或10%含有40mmol / l氯化钾的葡萄糖溶液中,使用聚丙烯容器进行输液。 这些溶液在室温下稳定24小时。 尽管稳定了一段时间,但一定量的胰岛素最初被输液系统的材料吸收。 在胰岛素输注期间,有必要不断监测血糖浓度。
过量
症状:胰岛素过量所需的一定剂量尚未建立,但如果根据患者的需要施用过高的剂量,低血糖可逐渐发展。
治疗:轻度低血糖,患者可以通过服用葡萄糖或含糖食物消除自己。 因此,鼓励糖尿病患者不断携带含糖食品。
在严重低血糖的情况下,当患者无意识时,应以/ m或s / c(受过训练的人员注射)或IV葡萄糖溶液(葡萄糖)注射0.5至1mg胰高血糖素(只有医务人员可以管理) 。 如果患者在引入胰高血糖素后10-15分钟内没有恢复意识,还需要注射IV葡萄糖。 恢复意识后,建议患者摄取富含碳水化合物的食物,以防止低血糖症复发。
特别说明
在与时区变化相关的长途旅行之前,患者应咨询其主治医师,因为更改时区意味着患者应在另一时间服用食物并注射胰岛素。
高血糖。 剂量不足或停止治疗,特别是1型糖尿病,可导致高血糖和糖尿病酮症酸中毒的发展。 一般来说,高血糖症状在几小时或几天内逐渐出现。 高血糖症状包括恶心,呕吐,嗜睡,皮肤发红和干燥,口干,尿量增加,口渴,食欲不振,以及呼出的空气中出现丙酮气味。 没有适当的治疗,高血糖可导致死亡。
低血糖症。 跳过膳食时,计划外增加的身体压力或与患者胰岛素剂量需求相关的太高可能导致低血糖。 补充碳水化合物代谢后,例如,通过强化胰岛素治疗,他们的典型症状 - 低血糖前体可能在患者中发生变化,应通知患者。 常见的症状 - 前体可以随着糖尿病持续而消失。
短效胰岛素类似物的药效学特征的结果是使用低血糖症的发展可能比使用可溶性人胰岛素的时候早。 由于NovoRapid®Penfill®/FlexPen®应与食物摄取直接相关,所以在治疗伴有疾病或服用LS的患者的治疗中,应考虑药物效应的高发生率,从而减缓吸收餐饮。
伴随疾病,特别是传染性疾病,伴有发烧,通常会增加身体对胰岛素的需求。 如果患者伴随肾脏,肝脏,肾上腺,垂体或甲状腺疾病的疾病,也可能需要更换药物的剂量。 当将患者转移到其他类型的胰岛素时,与先前类型的胰岛素相比,早期症状 - 低血糖的前体可能变得不那么显着。
从其他胰岛素制剂转移患者。 将患者转移到其他制造商的新型胰岛素或胰岛素制剂必须在严格的医疗监督下进行。 如果胰岛素制剂和/或制造方法的浓度,类型,生产者和物种(人胰岛素,动物来源的胰岛素,人胰岛素类似物)和/或制造方法改变,则可能需要与之前使用的剂量变化或注射频率的增加胰岛素制剂。 如果需要调整剂量,可以在药物的第一次给药或治疗的前几周或几个月内完成。
行政部门的反应。 与其他胰岛素制剂一样,注射部位的反应可以发展,其表现为疼痛,发红,荨麻疹,炎症,瘀伤,肿胀和瘙痒。 同一解剖区域的定期注射部位变化可以减轻症状或预防反应的发展。 在极少数情况下,可能需要取消NovoRapid®Penfill®/FlexPen®。
同时使用噻唑烷二酮组和胰岛素制剂的制剂。 已经报道了用于治疗噻唑烷二酮类与胰岛素制剂组合的患者的CHF病例,特别是如果这样的患者具有CHF的危险因素。 在使用噻唑烷二酮类和胰岛素制剂指定患者联合治疗时,应考虑到这一事实。 当这种联合疗法被规定时,有必要对患者进行身体检查,以确定CHF的体征和症状,体重增加和水肿。 如果患者心力衰竭症状恶化,应停用噻唑烷二酮治疗。
胰岛素抗体 使用胰岛素可以形成抗体。 在极少数情况下,抗体的形成可能需要校正胰岛素的剂量,以防止高血糖或低血糖的病例。
对驾驶车辆和机制工作的能力的影响。 在低血糖期间,患者集中精力和反应速度的能力可能会中断,这在这些能力特别有必要的情况下可能是危险的(例如,驾驶车辆或使用机器和机构时)。 建议患者采取措施,防止车辆管理中发生低血糖,并配合机制。 这对于缺乏或减少症状严重程度的患者尤其重要,即发生低血糖的前兆或频繁发生低血糖症的患者。
问题形式
用于皮下和静脉内给药的溶液为100单位/ ml。 将3ml水解玻璃瓶I,一侧用溴丁基橡胶/聚异戊二烯的圆盘密封,另一侧用溴丁基橡胶的活塞密封; 5个墨盒,PVC /铝箔泡罩; 1个水泡在一堆纸板。
对于在一侧用溴丁基橡胶/聚异戊二烯盘密封的溴丁基橡胶活塞的水解类玻璃1的药筒中的3ml药物,并在另一侧用多次注射器密封塑料多次一次性注射器笔。
对于多个注射的5个塑料多剂量一次性注射器笔放置在纸板箱中。
药店的休假条款
处方。
储存条件
在2-8℃的温度下(在冰箱中)。 但不在冰柜旁边。 不要冻结 将墨盒存放在纸板箱中,以防止其受到光照。 打开的墨盒:不要存放在冰箱里。 储存温度不超过30°C。使用4周内。
放在儿童接触不到的地方。
保质期
30个月
NovoRapid FlexPen 100 units/ml, solution for injection in a pre-filled pen.
What is a Patient Information Leaflet and why is it useful?
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.
Below is a text only representation of the Patient Information Leaflet. The original can be viewed in PDF format using the link above.
The text only version may be available from RNIB in large print, Braille or audio CD. For further information call RNIB Medicine Leaflet Line on 0800 198 5000. The product code(s) for this leaflet are: EU/1/99/119/011, EU/1/99/119/008, EU/1/99/119/020, EU/1/99/119/022, EU/1/99/119/023, EU/1/99/119/001, EU/1/99/119/009, EU/1/99/119/017, EU/1/99/119/021, EU/1/99/119/015, EU/1/99/119/003, EU/1/99/119/018, EU/1/99/119/010, EU/1/99/119/006, EU/1/99/119/019.
NovoRapid FlexPen 100 units/ml, solution for injection in a pre-filled pen.
Package leaflet: Information for the user
NovoRapid® FlexPen®
100 units/ml
Solution for injection in pre–filled pen
Insulin aspart
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
· Keep this leaflet. You may need to read it again.
· If you have any further questions, ask your doctor, nurse or pharmacist.
· This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
· If you get any side effects, talk with your doctor, nurse or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
What is in this leaflet
1. What NovoRapid® is and what it is used for
2. What you need to know before you use NovoRapid®
3. How to use NovoRapid®
4. Possible side effects
5. How to store NovoRapid®
6. Contents of the pack and other information
1. What NovoRapid® is and what it is used for
NovoRapid® is a modern insulin (insulin analogue) with a rapid–acting effect. Modern insulin products are improved versions of human insulin.
NovoRapid® is used to reduce the high blood sugar level in adults, adolescents and children aged 1 year and above with diabetes mellitus (diabetes). Diabetes is a disease where your body does not produce enough insulin to control the level of your blood sugar. Treatment with NovoRapid® helps to prevent complications from your diabetes.
NovoRapid® will start to lower your blood sugar 10–20 minutes after you inject it, a maximum effect occurs between 1 and 3 hours after the injection and the effect lasts for 3–5 hours. Due to this short action NovoRapid® should normally be taken in combination with intermediate-acting or long–acting insulin preparations.
2. What you need to know before you use NovoRapid®
Do not use NovoRapid®
· If you are allergic to insulin aspart, or any of the other ingredients in this medicine (see section 6, Contents of the pack and other information).
· If you suspect hypoglycaemia (low blood sugar) is starting (see a) Summary of serious and very common side effects in section 4).
· If FlexPen® is dropped, damaged or crushed.
· If it has not been stored correctly or been frozen (see section 5, How to store NovoRapid®).
· If the insulin does not appear clear and colourless.
If any of these applies, do not use NovoRapid®. Talk with your doctor, nurse or pharmacist for advice.
Before using NovoRapid®
· Check the label to make sure it is the right type of insulin.
· Always use a new needle for each injection to prevent contamination.
· Needles and NovoRapid® FlexPen® must not be shared.
· NovoRapid® FlexPen® is only suitable for injecting under the skin. Speak to your doctor if you need to inject your insulin by another method.
Warnings and precautions
Some conditions and activities can affect your need for insulin. Consult your doctor:
· If you have trouble with your kidneys or liver, or with your adrenal, pituitary or thyroid glands.
· If you exercise more than usual or if you want to change your usual diet, as this may affect your blood sugar level.
· If you are ill, carry on taking your insulin and consult your doctor.
· If you are going abroad, travelling over time zones may affect your insulin needs and the timing of your injections.
Children and adolescents
Do not give this medicine to children below 1 year of age since no clinical studies have been carried out in children below the age of 1 year.
Other medicines and NovoRapid®
Tell your doctor, nurse or pharmacist if you are taking, have recently taken or might take any other medicines.
Some medicines affect your blood sugar level and this may mean that your insulin dose has to change. Listed below are the most common medicines which may affect your insulin treatment.
Your blood sugar level may fall (hypoglycaemia) if you take:
· Other medicines for the treatment of diabetes
· Monoamine oxidase inhibitors (MAOI) (used to treat depression)
· Beta-blockers (used to treat high blood pressure)
· Angiotensin converting enzyme (ACE) inhibitors (used to treat certain heart conditions or high blood pressure)
· Salicylates (used to relieve pain and lower fever)
· Anabolic steroids (such as testosterone)
· Sulphonamides (used to treat infections).
Your blood sugar level may rise (hyperglycaemia) if you take:
· Oral contraceptives (birth control pills)
· Thiazides (used to treat high blood pressure or excessive fluid retention)
· Glucocorticoids (such as ‘cortisone’ used to treat inflammation)
· Thyroid hormones (used to treat thyroid gland disorders)
· Sympathomimetics (such as epinephrine [adrenaline], or salbutamol, terbutaline used to treat asthma)
· Growth hormone (medicine for stimulation of skeletal and somatic growth and pronounced influence on the body’s metabolic processes)
· Danazol (medicine acting on ovulation).
Octreotide and lanreotide (used for treatment of acromegaly, a rare hormonal disorder that usually occurs in middle-aged adults, caused by the pituitary gland producing excess growth hormone) may either increase or decrease your blood sugar level.
Beta-blockers (used to treat high blood pressure) may weaken or suppress entirely the first warning symptoms which help you to recognise low blood sugar.
Pioglitazone (tablets used for the treatment of type 2 diabetes)
Some patients with long-standing type 2 diabetes and heart disease or previous stroke who were treated with pioglitazone and insulin experienced the development of heart failure. Inform your doctor as soon as possible if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema).
If you have taken any of the medicines listed here, tell your doctor, nurse or pharmacist.
Drinking alcohol and taking NovoRapid®
· If you drink alcohol, your need for insulin may change as your blood sugar level may either rise or fall. Careful monitoring is recommended.
Pregnancy and breast-feeding
· If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. NovoRapid® can be used during pregnancy. Your insulin dose may need to be changed during pregnancy and after delivery. Careful control of your diabetes, particularly prevention of hypoglycaemia, is important for the health of your baby.
· There are no restrictions on treatment with NovoRapid® during breast-feeding.
Ask your doctor, nurse or pharmacist for advice before taking this medicine while pregnant or breast-feeding.
Driving and using machines
· Please ask your doctor whether you can drive a car or operate a machine:
o If you have frequent hypoglycaemia.
o If you find it hard to recognise hypoglycaemia.
If your blood sugar is low or high, your concentration and ability to react might be affected and therefore also your ability to drive or operate a machine. Bear in mind that you could endanger yourself or others.
NovoRapid® has a rapid onset of effect therefore if hypoglycaemia occurs, you may experience it earlier after an injection when compared to soluble human insulin.
Important information about some of the ingredients of NovoRapid®
NovoRapid® contains less than 1 mmol sodium (23 mg) per dose, i.e. NovoRapid® is essentially ‘sodium-free’.
3. How to use NovoRapid®
Dose and when to take your insulin
Always use your insulin and adjust your dose exactly as your doctor has told you. Check with your doctor, nurse or pharmacist if you are not sure.
NovoRapid® is generally taken immediately before a meal. Eat a meal or snack within 10 minutes of the injection to avoid low blood sugar. When necessary, NovoRapid® can be given soon after a meal. See How and where to inject below for information.
Do not change your insulin unless your doctor tells you to. If your doctor has switched you from one type or brand of insulin to another, your dose may have to be adjusted by your doctor.
Use in children and adolescents
NovoRapid® can be used in adolescents and children aged 1 year and above instead of soluble human insulin when a rapid onset of effect is preferred. For example, when it is difficult to dose the child in relation to meals.
Use in special patient groups
If you have reduced kidney or liver function, or if you are above 65 years of age, you need to check your blood sugar more regularly and discuss changes in your insulin dose with your doctor.
How and where to inject
NovoRapid® is for injection under the skin (subcutaneously). You must never inject yourself directly into a vein (intravenously) or muscle (intramuscularly). NovoRapid® FlexPen® is only suitable for injecting under the skin. Speak to your doctor if you need to inject your insulin by another method.
With each injection, change the injection site within the particular area of skin that you use. This may reduce the risk of developing lumps or skin pitting (see section 4, Possible side effects). The best places to give yourself an injection are: the front of your waist (abdomen), the upper arm or the front of your thighs. The insulin will work more quickly if injected into the front of your waist. You should always measure your blood sugar regularly.
How to handle NovoRapid® FlexPen®
NovoRapid® FlexPen® is a pre-filled, colour-coded, disposable pen containing insulin aspart.
Read carefully the instructions on how to use NovoRapid® FlexPen® included in this package leaflet. You must use the pen as described in the instructions on how to use NovoRapid® FlexPen®.
Always ensure you use the correct pen before you inject your insulin.
If you take more insulin than you should
If you take too much insulin your blood sugar gets too low (hypoglycaemia). See a) Summary of serious and very common side effects in section 4.
If you forget to take your insulin
If you forget to take your insulin your blood sugar may get too high (hyperglycaemia). See c) Effects from diabetes in section 4.
If you stop taking your insulin
Do not stop taking your insulin without speaking with a doctor, who will tell you what needs to be done. This could lead to very high blood sugar (severe hyperglycaemia) and ketoacidosis. See c) Effects from diabetes in section 4.
If you have any further questions on the use of this medicine, ask your doctor, nurse or pharmacist.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
a) Summary of serious and very common side effects
Low blood sugar (hypoglycaemia) is a very common side effect. It may affect more than 1 in 10 people.
Low blood sugar may occur if you:
· Inject too much insulin.
· Eat too little or miss a meal.
· Exercise more than usual.
· Drink alcohol (see Drinking alcohol and taking NovoRapid® in section 2).
Signs of low blood sugar: Cold sweat; cool pale skin; headache; rapid heartbeat; feeling sick; feeling very hungry; temporary changes in vision; drowsiness; unusual tiredness and weakness; nervousness or tremor; feeling anxious; feeling confused; difficulty in concentrating.
Severe low blood sugar can lead to unconsciousness. If prolonged severe low blood sugar is not treated, it can cause brain damage (temporary or permanent) and even death. You may recover more quickly from unconsciousness with an injection of the hormone glucagon by someone who knows how to use it. If you are given glucagon, you will need glucose or a sugar snack as soon as you are conscious. If you do not respond to glucagon treatment, you will have to be treated in a hospital.
What to do if you experience low blood sugar:
· If you experience low blood sugar, eat glucose tablets or another high sugar snack (e.g. sweets, biscuits, fruit juice). Measure your blood sugar if possible and rest. Always carry glucose tablets or high sugar snacks with you, just in case.
· When symptoms of low blood sugar have disappeared or when blood sugar level is stabilised, continue insulin treatment as usual.
· If you have such a low blood sugar that it makes you pass out, if you have had need for injection of glucagon, or if you have experienced many incidents of low blood sugar, talk with a doctor. The amount or timing of insulin, food or exercise may need to be adjusted.
Tell relevant people that you have diabetes and what the consequences may be, including the risk of passing out (become unconscious) due to low blood sugar. Let them know that if you pass out, they must turn you on your side and get medical help straight away. They must not give you any food or drink due to risk of suffocation.
Serious allergic reactions to NovoRapid® or one of its ingredients (called a systemic allergic reaction) is a very rare side effect but can potentially be life threatening. It may affect less than 1 in 10,000 people.
Seek medical advice immediately:
· If signs of allergy spread to other parts of your body.
· If you suddenly feel unwell, and you: start sweating; start being sick (vomiting); have difficulty in breathing; have a rapid heartbeat; feel dizzy.
· If you notice any of these signs, seek medical advice immediately.
b) List of other side effects
Uncommon side effects
May affect less than 1 in 100 people.
Signs of allergy: Local allergic reactions (pain, redness, hives, inflammation, bruising, swelling and itching) at the injection site may occur. These usually disappear after a few weeks of taking your insulin. If they do not disappear, or if they spread throughout your body, talk to your doctor immediately. See also Serious allergic reactions above.
Vision problems: When you first start your insulin treatment, it may disturb your vision, but the disturbance is usually temporary.
Changes at the injection site (lipodystrophy): The fatty tissue under the skin at the injection site may shrink (lipoatrophy) or thicken (lipohypertrophy). Changing the site with each injection reduces the risk of developing such skin changes. If you notice your skin pitting or thickening at the injection site, tell your doctor or nurse. These reactions can become more severe, or they may change the absorption of your insulin, if you inject in such a site.
Swollen joints: When you start taking insulin, water retention may cause swelling around your ankles and other joints. Normally this soon disappears. If not, talk to your doctor.
Diabetic retinopathy (an eye disease related to diabetes which can lead to loss of vision): If you have diabetic retinopathy and your blood sugar level improves very fast, the retinopathy may get worse. Ask your doctor about this.
Rare side effects
May affect less than 1 in 1,000 people.
Painful neuropathy (pain due to nerve damage): If your blood sugar level improves very fast, you may get nerve related pain. This is called acute painful neuropathy and is usually transient.
Reporting of side effects
If you get any side effects, talk with your doctor, nurse or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via
Ireland
HPRA Pharmacovigilance
Earlsfort Terrace
IRL - Dublin 2
Tel: +353 1 6764971
Fax: +353 1 6762517
Website: www.hpra.ie
e-mail: medsafety@hpra.ie
United Kingdom
Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard
or search for MHRA Yellow Card in the Google Play or Apple App Store.
By reporting side effects you can help provide more information on the safety of this medicine.
c) Effects from diabetes
High blood sugar (hyperglycaemia)
High blood sugar may occur if you:
· Have not injected enough insulin.
· Forget to inject your insulin or stop taking insulin.
· Repeatedly inject less insulin than you need.
· Get an infection and/or a fever.
· Eat more than usual.
· Exercise less than usual.
Warning signs of high blood sugar:
The warning signs appear gradually. They include: increased urination; feeling thirsty; losing your appetite; feeling sick (nausea or vomiting); feeling drowsy or tired; flushed; dry skin; dry mouth and a fruity (acetone) smell of the breath.
What to do if you experience high blood sugar:
· If you get any of the above signs: test your blood sugar level, test your urine for ketones if you can, then seek medical advice immediately.
· These may be signs of a very serious condition called diabetic ketoacidosis (build-up of acid in the blood because the body is breaking down fat instead of sugar). If you do not treat it, this could lead to diabetic coma and eventually death.
5. How to store NovoRapid®
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the FlexPen® label and carton, after ‘EXP’. The expiry date refers to the last day of that month.
Always keep the pen cap on your FlexPen® when you are not using it in order to protect it from light.
NovoRapid® must be protected from excessive heat and light.
Before opening: NovoRapid® FlexPen® that is not being used is to be stored in the refrigerator at 2°C to 8°C, away from the cooling element. Do not freeze.
During use or when carried as a spare: You can carry your NovoRapid FlexPen with you and keep it at a temperature below 30°C or in a refrigerator (2˚C to 8˚C) for up to 4 weeks. If refrigerated, keep away from the cooling element. Do not freeze.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information
What NovoRapid® contains
· The active substance is insulin aspart. Each ml contains 100 units of insulin aspart. Each pre-filled pen contains 300 units of insulin aspart in 3 ml solution for injection.
· The other ingredients are glycerol, phenol, metacresol, zinc chloride, disodium phosphate dihydrate, sodium chloride, hydrochloric acid, sodium hydroxide and water for injections.
What NovoRapid® looks like and contents of the pack
NovoRapid® is presented as a solution for injection.
Pack sizes of 1 (with or without needles), 5 (without needles) and 10 (without needles) pre-filled pens of 3 ml. Not all pack sizes may be marketed.
The solution is clear and colourless.
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder
Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd
Denmark
Manufacturer
The manufacturer can be identified by the batch number printed on the slip of the carton and on the label:
· If the second and third characters are S6, P5, K7, R7, VG, FG or ZF, the manufacturer is
Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd
Denmark
· If the second and third characters are H7 or T6, the manufacturer is
Novo Nordisk Production SAS
45 Avenue d’Orléans
F-28000 Chartres
France
Now turn over for information on how to use your FlexPen®.
This leaflet was last revised in 04/2018
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.
NovoRapid®, FlexPen®, NovoFine® and NovoTwist®
are trademarks owned by Novo Nordisk A/S, Denmark
© 2018
Novo Nordisk A/S
Instructions on how to use NovoRapid® solution for injection in FlexPen®.
Read the following instructions carefully before using your FlexPen®. If you do not follow the instructions carefully, you may get too little or too much insulin, which can lead to too high or too low blood sugar level.
Your FlexPen® is a pre-filled dial-a-dose insulin pen. You can select doses from 1 to 60 units in increments of 1 unit. FlexPen® is designed to be used with NovoFine® or NovoTwist® disposable needles up to a length of 8 mm. As a precautionary measure, always carry a spare insulin delivery device in case your FlexPen® is lost or damaged.
Caring for your pen
Your FlexPen® must be handled with care.
If it is dropped, damaged or crushed, there is a risk of insulin leakage. This may cause inaccurate dosing, which can lead to too high or too low blood sugar level.
You can clean the exterior of your FlexPen® by wiping it with a medicinal swab. Do not soak it, wash or lubricate it as it may damage the pen.
Do not refill your FlexPen®. Once empty, it must be disposed of.
Preparing your NovoRapid® FlexPen®
Check the name and coloured label of your pen to make sure that it contains the correct type of insulin. This is especially important if you take more than one type of insulin. If you take the wrong type of insulin, your blood sugar level may get too high or too low.
A
Pull off the pen cap.
B
Remove the paper tab from a new disposable needle.
Screw the needle straight and tightly onto your FlexPen®.
C
Pull off the big outer needle cap and keep it for later.
D
Pull off the inner needle cap and dispose of it.
Never try to put the inner needle cap back on the needle. You may stick yourself with the needle.
Always use a new needle for each injection. This reduces the risk of contamination, infection, leakage of insulin, blocked needles and inaccurate dosing.
Be careful not to bend or damage the needle before use.
Checking the insulin flow
Prior to each injection small amounts of air may collect in the cartridge during normal use. To avoid injection of air and ensure proper dosing:
E
Turn the dose selector to select 2 units.
F
Hold your FlexPen® with the needle pointing upwards and tap the cartridge gently with your finger a few times to make any air bubbles collect at the top of the cartridge.
G
Keeping the needle upwards, press the push–button all the way in. The dose selector returns to 0.
A drop of insulin should appear at the needle tip. If not, change the needle and repeat the procedure no more than 6 times.
If a drop of insulin still does not appear, the pen is defective, and you must use a new one.
Always make sure that a drop appears at the needle tip before you inject. This makes sure that the insulin flows. If no drop appears, you will not inject any insulin, even though the dose selector may move. This may indicate a blocked or damaged needle.
Always check the flow before you inject. If you do not check the flow, you may get too little insulin or no insulin at all. This may lead to too high blood sugar level.
Selecting your dose
Check that the dose selector is set at 0.
H
Turn the dose selector to select the number of units you need to inject.
The dose can be corrected either up or down by turning the dose selector in either direction until the correct dose lines up with the pointer. When turning the dose selector, be careful not to push the push-button as insulin will come out.
You cannot select a dose larger than the number of units left in the cartridge.
Always use the dose selector and the pointer to see how many units you have selected before injecting the insulin.
Do not count the pen clicks. If you select and inject the wrong dose, your blood sugar level may get too high or too low. Do not use the residual scale, it only shows approximately how much insulin is left in your pen.
Making the injection
Insert the needle into your skin. Use the injection technique shown by your doctor or nurse.
I
Inject the dose by pressing the push-button all the way in until 0 lines up with the pointer. Be careful only to push the push–button when injecting.
Turning the dose selector will not inject insulin.
J
Keep the push-button fully depressed and let the needle remain under the skin for at least 6 seconds. This will make sure you get the full dose.
Withdraw the needle from the skin, then release the pressure on the push-button.
Always make sure that the dose selector returns to 0 after the injection. If the dose selector stops before it returns to 0, the full dose has not been delivered, which may result in too high blood sugar level.
K
Lead the needle into the big outer needle cap without touching it. When the needle is covered, carefully push the big outer needle cap completely on and then unscrew the needle.
Dispose of it carefully and put the pen cap back on.
Always remove the needle after each injection and store your FlexPen® without the needle attached. This reduces the risk of contamination, infection, leakage of insulin, blocked needles and inaccurate dosing.
Further important information
Caregivers must be very careful when handling used needles – to reduce the risk of needle sticks and cross-infection.
Dispose of your used FlexPen® carefully without the needle attached.
Never share your pen or your needles with other people. It might lead to cross-infection.
Never share your pen with other people. Your medicine might be harmful to their health.
Always keep your pen and needles out of sight and reach of others, especially children.